Plasma GFAP for populational enrichment of clinical trials in preclinical Alzheimer's disease
Alzheimer's & Dementia · 2025-05 · 21 (5)
DOI: 10.1002/alz.70209 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 09.05.2025. Verfasst von Bruna Bellaver und 36 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Glial Fibrillary Acidic Protein, Alzheimer Disease, Clinical Trials as Topic. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, Aina (Ann) Wallströms, Gamla Tjänarinnor Foundation.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION Cognitively unimpaired (CU) amyloid beta (Aβ)+ individuals with elevated plasma glial fibrillary acidic protein (GFAP) have an increased risk of Alzheimer's disease (AD)‐related progression. We tested the utility of plasma GFAP for population enrichment CU populations in clinical trials. METHODS We estimated longitudinal progression, effect size, and costs of hypothetical clinical trials designed to test an estimated 25% drug effect on reducing tau positron emission tomography (PET) accumulation in the medial temporal lobe (MTL) and temporal neocortical region (NEO‐T). RESULTS CU GFAP+/Aβ+ individuals present an increased annual rate of change and effect size in tau PET MTL and tau PET NEO‐T compared to the other groups. An enrichment strategy selecting CU GFAP+/Aβ+ individuals would require a smaller sample size (≈ 57% reduction) and fewer Aβ PET scans (≈ 74% reduction) than trials enriched with Aβ PET alone, reducing total clinical trial costs by up to 64%. DISCUSSION Our results suggest that clinical trials focusing on preclinical AD recruiting Aβ+ individuals with elevated GFAP levels would improve cost effectiveness. Highlights Cognitively unimpaired (CU) glial fibrillary acidic protein (GFAP)+/amyloid beta (Aβ)+ shows increased changes in tau positron emission tomography (PET) . CU GFAP+/Aβ+ enriched clinical trials require a reduced sample size compared to Aβ+ only. CU GFAP+/Aβ+ enrichment reduces Aβ PET scans required and costs. CU GFAP+/Aβ+ enrichment allows the selection of individuals at early stages of the Alzheimer's disease continuum.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Graduate Program in Biological Sciences: Biochemistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
- Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services socia…
- Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.
- Lawrence Berkeley National Laboratory, Berkeley, California, USA.
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
ORCID-Profile: Tharick A Pascoal
Förderung
- NIA NIH HHS
- Aina (Ann) Wallströms
- Gamla Tjänarinnor Foundation
- ALF-agreement
- Fonds de Recherche du Québec-Santé
- CIHR
- Mary-Ann Sjöbloms Foundation
- Swedish Dementia Foundation
Zitieren
APA
Bellaver, B., Povala, G., Ferreira, P. C. L., Bauer-Negrini, G., Lussier, F. Z., Leffa, D. T., Ferrari-Souza, J. P., Rodrigues, M. S., Amaral, L., Oliveira, M. S., Soares, C., Rocha, A., Saha, P., Rahmouni, N., Macedo, A., Tissot, C., Therriault, J., Servaes, S., Klostranec, J., …, & Pascoal, T. A. (2025). Plasma GFAP for populational enrichment of clinical trials in preclinical Alzheimer's disease. Alzheimer's & Dementia, 21(5). https://doi.org/10.1002/alz.70209
Vancouver
Bellaver B, Povala G, Ferreira PCL, Bauer-Negrini G, Lussier FZ, Leffa DT, et al. Plasma GFAP for populational enrichment of clinical trials in preclinical Alzheimer's disease. Alzheimer's & Dementia. 2025;21(5). doi:10.1002/alz.70209
BibTeX
@article{Bellaver2025,
author = {Bellaver, Bruna and Povala, Guilherme and Ferreira, Pamela C L and Bauer-Negrini, Guilherme and Lussier, Firoza Z and Leffa, Douglas T and Ferrari-Souza, João Pedro and Rodrigues, Matheus S and Amaral, Livia and Oliveira, Markley S and Soares, Carolina and Rocha, Andreia and Saha, Pampa and Rahmouni, Nesrine and Macedo, Arthur and Tissot, Cécile and Therriault, Joseph and Servaes, Stijn and Klostranec, Jesse and Montembeault, Maxime and Benedet, Andréa L and Ashton, Nicholas J and Koscik, Rebecca Langhough and Betthauser, Tobey J and Christian, Brad T and Wilson, Rachael and Triana-Baltzer, Gallen and Vitali, Paolo and Gauthier, Serge and Zetterberg, Henrik and Blennow, Kaj and Karikari, Thomas K and Tudorascu, Dana and Zimmer, Eduardo R and Johnson, Sterling and Rosa-Neto, Pedro and Pascoal, Tharick A},
title = {Plasma GFAP for populational enrichment of clinical trials in preclinical Alzheimer's disease},
journal = {Alzheimer's & Dementia},
year = {2025},
volume = {21},
number = {5},
doi = {10.1002/alz.70209}
}
EUVIMED